BridgeBio Pharma (NASDAQ:BBIO) Stock Sale Disclosed by Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO). In a filing disclosed on October 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in BridgeBio Pharma stock on September 29th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Benchmark Electronics (NYSE:BHE) on 10/1/2026.
• Sold $1,001 – $15,000 in shares of Oxford Industries (NYSE:OXM) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 9/29/2026.
• Sold $15,001 – $50,000 in shares of ITT (NYSE:ITT) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Tandem Diabetes Care (NASDAQ:TNDM) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Cytokinetics (NASDAQ:CYTK) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of YETI (NYSE:YETI) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of AtriCure (NASDAQ:ATRC) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Alkermes (NASDAQ:ALKS) on 9/29/2026.

BridgeBio Pharma Trading Down 3.7%

Shares of BBIO stock opened at $63.30 on Wednesday. The stock has a 50 day moving average of $73.77 and a two-hundred day moving average of $73.44. The company has a market capitalization of $12.37 billion, a P/E ratio of -17.73 and a beta of 0.97. BridgeBio Pharma, Inc. has a 12 month low of $52.75 and a 12 month high of $93.42.

BridgeBio Pharma (NASDAQ:BBIO) last issued its earnings results on Monday, August 10th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.20). The company had revenue of $243.68 million during the quarter, compared to analysts’ expectations of $220.91 million. BridgeBio Pharma’s revenue for the quarter was up 120.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.95) earnings per share. Sell-side analysts predict that BridgeBio Pharma, Inc. will post -2.66 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on BBIO. Bank of America boosted their target price on shares of BridgeBio Pharma from $101.00 to $104.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Cantor Fitzgerald reiterated an “overweight” rating on shares of BridgeBio Pharma in a research report on Monday, October 5th. UBS Group reissued a “buy” rating on shares of BridgeBio Pharma in a report on Wednesday, September 2nd. Mizuho lifted their price target on shares of BridgeBio Pharma from $96.00 to $110.00 and gave the company an “outperform” rating in a report on Tuesday, September 1st. Finally, Morgan Stanley reduced their price target on shares of BridgeBio Pharma from $98.00 to $97.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 11th. Twenty-one equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $105.42.

Hedge Funds Weigh In On BridgeBio Pharma

A number of institutional investors have recently modified their holdings of BBIO. Jupiter Topco LLC acquired a new position in shares of BridgeBio Pharma during the second quarter valued at $1,050,762,000. Janus Henderson Group PLC boosted its stake in shares of BridgeBio Pharma by 19.8% in the 1st quarter. Janus Henderson Group PLC now owns 13,179,013 shares of the company’s stock valued at $978,608,000 after purchasing an additional 2,178,556 shares during the last quarter. Brooklands Fund Management Ltd bought a new position in shares of BridgeBio Pharma in the 4th quarter valued at about $210,348,000. The Manufacturers Life Insurance Company acquired a new stake in shares of BridgeBio Pharma during the 2nd quarter worth approximately $145,663,000. Finally, Pictet Asset Management Holding SA grew its position in shares of BridgeBio Pharma by 8.7% during the 1st quarter. Pictet Asset Management Holding SA now owns 1,381,184 shares of the company’s stock worth $101,495,000 after buying an additional 110,894 shares during the period. 99.85% of the stock is owned by institutional investors.

Insider Buying and Selling

In other BridgeBio Pharma news, CEO Neil Kumar sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $69.08, for a total value of $690,800.00. Following the transaction, the chief executive officer directly owned 495,686 shares of the company’s stock, valued at approximately $34,241,988.88. This trade represents a 1.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Maricel Apuli sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $80.06, for a total transaction of $160,120.00. Following the completion of the transaction, the chief accounting officer directly owned 127,401 shares in the company, valued at approximately $10,199,724.06. The trade was a 1.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 56,980 shares of company stock valued at $4,578,119. 14.23% of the stock is currently owned by insiders.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a biotechnology company focused on discovering, developing and commercializing medicines for genetically driven diseases. The company uses its drug discovery and development platform to advance therapies across areas including rare diseases, genetic disorders and precision oncology, with programs designed to address the underlying biological causes of disease.

BridgeBio operates through a collection of subsidiary companies and development programs. Its portfolio has included therapies for cardiovascular, endocrine, neurological and oncological conditions.